No Interaction Expected
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pretomanid is metabolized in the liver via multiple reductive and oxidative pathways with CYP3A4 mediated metabolism representing 20% of its metabolism. Pretomanid inhibits OAT3 but this is unlikely to cause a clinically significant interaction with tenofovir-DF as it is mainly eliminated by OAT1.
View all available interactions with
Tenofovir-DF (TDF) by clicking